Similarly, hyperactivation of the PI3K-AKT pathway contributes to metabolic reprogramming, increased survival, and therapeutic resistance, highlighting the potential value of dual targeting of MAPK and PI3K in KRAS-mutated cancer. The gene discussed is AKT1; the disease is cancer.